🇺🇸 FDA
Pipeline program

Recombinant human tissue kallikrein

DM199-2021-001

Phase 3 small_molecule active

Quick answer

Recombinant human tissue kallikrein for Acute Stroke is a Phase 3 program (small_molecule) at DiaMedica Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
DiaMedica Therapeutics
Indication
Acute Stroke
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials